Skip to content

Disability of Musculoskeletal Origin in Community-dwelling Elderly

Disability of Musculoskeletal Origin in Community-dwelling Elderly: Efficacy of a Specific Clinical Intervention.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00311103
Acronym
DIME
Enrollment
214
Registered
2006-04-05
Start date
2005-10-31
Completion date
2008-05-31
Last updated
2014-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases

Keywords

Elderly, Disability, Musculoskeletal diseases

Brief summary

Objectives: To assess the efficacy of an intervention program targeted to the elderly with recent-onset disability of musculoskeletal origin (DIMS), and to perform its economic evaluation.

Detailed description

Methodology: 1) Controlled randomised intervention study (3 years). Subjects: persons older than 65 in health district 7 of Madrid with acute (\< 3 months) DIMS. Intervention group patients will be attended by rheumatologists acording with clinical (diagnostic and therapeutical) protocols. Control group will receive the routine attention from the Health System. Efficacy and costs variables will be collected through monthly structured telephone interviews performed by independent personnel blinded to the intervention group. Efficacy will be measured by differences between groups regarding: 1) time to improvement in the baseline DIMS episode, 2) number of subsequent DIMS, and 3) total number of DIMS days. An economic evaluation will be performed from a societal perspective.

Interventions

PROCEDURESpecific clinical care program

The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).

Sponsors

Fundacion MAPFRE
CollaboratorOTHER
Fundación Mutua Madrileña
CollaboratorOTHER
Instituto de Salud Carlos III
CollaboratorOTHER_GOV
La Caixa Foundation
CollaboratorOTHER
Spanish Foundation of Rheumatology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Musculoskeletal disorder * Older than 64 years * To have disability measured with a) or b): 1. Rosser clasification: at least 4. 2. M.Gill questionnaire: To need help from other person to dress, to tidy up itself, to walk or to stand up. * Disability of recent onset:less than three months.(Patiens had a better functional situation before)

Exclusion criteria

* Recent surgery * Dementia with no family support * Institutionalized

Design outcomes

Primary

MeasureTime frame
Total number of DIMS daysPeriod of time in days until the patients recovers defined as: an improvement in at least one point in the Rosser disability level
Time to improvement in the baseline recent-onset disability episode of musculoskeletal origin (DIMS)Period of time in days until the patients recovers defined as: an improvement in at least one point in the Rosser disability level
Number of subsequent DIMSPeriod of time in days until the patients recovers defined as: an improvement in at least one point in the Rosser disability level

Secondary

MeasureTime frame
Direct and Indirect CostsPeriod of time in days until the patients recovers defined as: an improvement in at least one point in the Rosser disability level

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026